Background Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous
disease in which molecular stratification is needed to improve clinical outcomes. The
identification of predictive biomarkers can have a major impact on the care of these patients,
but the availability of metastatic tissue samples for research in this setting is limited.
Objective To study the prevalence of immune biomarkers of potential clinical utility to
immunotherapy in mCRPC and to determine their association with overall survival (OS) …